Cargando…

The tyrosine kinase inhibitor Dasatinib reduces cardiac steatosis and fibrosis in obese, type 2 diabetic mice

BACKGROUND: Cardiac steatosis is an early yet overlooked feature of diabetic cardiomyopathy. There is no available therapy to treat this condition. Tyrosine kinase inhibitors (TKIs) are used as first or second-line therapy in different types of cancer. In cancer patients with diabetes mellitus, TKIs...

Descripción completa

Detalles Bibliográficos
Autores principales:	Gu, Yue, Avolio, Elisa, Alvino, Valeria V, Thomas, Anita C, Herman, Andrew, Miller, Poppy J, Sullivan, Niall, Faulkner, Ashton, Madeddu, Paolo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2023
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10436421/ https://www.ncbi.nlm.nih.gov/pubmed/37592236 http://dx.doi.org/10.1186/s12933-023-01955-9

Ejemplares similares

Pulmonary hypertension with dasatinib and other tyrosine kinase inhibitors
por: El-Dabh, Ashraf, et al.
Publicado: (2019)

Personalized Cardiovascular Regenerative Medicine: Targeting the Extreme Stages of Life
por: Madeddu, Paolo, et al.
Publicado: (2019)

The tyrosine kinase inhibitor dasatinib (SPRYCEL) inhibits chondrocyte activity and proliferation
por: Vandyke, K, et al.
Publicado: (2011)

A combination of tyrosine kinase inhibitors, crizotinib and dasatinib for the treatment of glioblastoma multiforme
por: Nehoff, Hayley, et al.
Publicado: (2015)

Treatment Effects of the Second-Generation Tyrosine Kinase Inhibitor Dasatinib on Autoimmune Arthritis
por: Guo, Kai, et al.
Publicado: (2019)

Activation of Bone Marrow Adaptive Immunity in Type 2 Diabetes: Rescue by Co-stimulation Modulator Abatacept
por: Santopaolo, Marianna, et al.
Publicado: (2021)

Umbilical Cord Pericytes Provide a Viable Alternative to Mesenchymal Stem Cells for Neonatal Vascular Engineering
por: Cathery, William, et al.
Publicado: (2021)

Multi tyrosine kinase inhibitor dasatinib as novel cause of severe pre-capillary pulmonary hypertension?
por: Hennigs, Jan K, et al.
Publicado: (2011)

Dasatinib inhibits site-specific tyrosine phosphorylation of androgen receptor by Ack1 and Src kinases
por: Liu, Yuanbo, et al.
Publicado: (2010)

Epithelial Transfer of the Tyrosine Kinase Inhibitors Erlotinib, Gefitinib, Afatinib, Crizotinib, Sorafenib, Sunitinib, and Dasatinib: Implications for Clinical Resistance
por: Honeywell, Richard J., et al.
Publicado: (2020)

Effects of dasatinib on EphA2 receptor tyrosine kinase activity and downstream signalling in pancreatic cancer
por: Chang, Q, et al.
Publicado: (2008)

Stable Fatty Acid Solvates of Dasatinib, a Tyrosine Kinase Inhibitor: Prediction, Process, and Physicochemical Properties
por: Saladi, Venkata Narasayya, et al.
Publicado: (2022)

The Tyrosine Kinase Inhibitor Dasatinib Induces a Marked Adipogenic Differentiation of Human Multipotent Mesenchymal Stromal Cells
por: Borriello, Adriana, et al.
Publicado: (2011)

Modelling ponatinib resistance in tyrosine kinase inhibitor-naïve and dasatinib resistant BCR-ABL1+ cell lines
por: Lu, Liu, et al.
Publicado: (2018)

Immunomodulatory Activity of the Tyrosine Kinase Inhibitor Dasatinib to Elicit NK Cytotoxicity against Cancer, HIV Infection and Aging
por: Rodríguez-Agustín, Andrea, et al.
Publicado: (2023)

In Vitro and In Vivo Preclinical Testing of Pericyte‐Engineered Grafts for the Correction of Congenital Heart Defects
por: Alvino, Valeria Vincenza, et al.
Publicado: (2020)

Approaches for the isolation and long-term expansion of pericytes from human and animal tissues
por: Alvino, Valeria Vincenza, et al.
Publicado: (2023)

B-lymphoid tyrosine kinase (Blk) is an oncogene and a potential target for therapy with dasatinib in cutaneous T-cell lymphoma (CTCL)
por: Petersen, D L, et al.
Publicado: (2014)

Innate T-αβ lymphocytes as new immunological components of anti-tumoral “off-target” effects of the tyrosine kinase inhibitor dasatinib
por: Barbarin, Alice, et al.
Publicado: (2020)

Effects of the STAMP-inhibitor asciminib on T cell activation and metabolic fitness compared to tyrosine kinase inhibition by imatinib, dasatinib, and nilotinib
por: Häselbarth, Lukas, et al.
Publicado: (2023)

Dasatinib targets c-Src kinase in cardiotoxicity
por: Elmadani, Manar, et al.
Publicado: (2023)

Accelerated Cardiac Aging in Patients With Congenital Heart Disease
por: Iacobazzi, Dominga, et al.
Publicado: (2022)

Corrigendum: Accelerated cardiac aging in patients with congenital heart disease
por: Iacobazzi, Dominga, et al.
Publicado: (2022)

Concise Review: The Regenerative Journey of Pericytes Toward Clinical Translation
por: Cathery, William, et al.
Publicado: (2018)

Combination therapy of BCR-ABL-positive B cell acute lymphoblastic leukemia by tyrosine kinase inhibitor dasatinib and c-JUN N-terminal kinase inhibition
por: Xiao, Xinhua, et al.
Publicado: (2020)

Dasatinib Reduces Lung Inflammation and Fibrosis in Acute Experimental Silicosis
por: Cruz, Fernanda Ferreira, et al.
Publicado: (2016)

Dasatinib Attenuates Fibrosis in Keloids by Decreasing Senescent Cell Burden
por: DARMAWAN, Claudia C., et al.
Publicado: (2023)

Editorial: Inflammation, Metabolism and Epigenetics in Valvular Heart Disease
por: Jover, Eva, et al.
Publicado: (2022)

Reconstruction of the Swine Pulmonary Artery Using a Graft Engineered With Syngeneic Cardiac Pericytes
por: Alvino, Valeria Vincenza, et al.
Publicado: (2021)

Role of Receptor Tyrosine Kinase Signaling in Renal Fibrosis
por: Liu, Feng, et al.
Publicado: (2016)

VEGFR1-tyrosine kinase signaling in pulmonary fibrosis
por: Amano, Hideki, et al.
Publicado: (2021)

Case report: Pleural effusion during tyrosine-kinase inhibitor treatment in chronic myeloid leukemia: Not only a dasatinib-related adverse event
por: Pasquale, Raffaella, et al.
Publicado: (2022)

A case report of sudden cardiac arrest and torsade de pointes induced by the second-generation tyrosine kinase inhibitor dasatinib combined with fluconazole
por: Yuan, Yuting, et al.
Publicado: (2023)

Dose optimization strategy of the tyrosine kinase inhibitors imatinib, dasatinib, and nilotinib for chronic myeloid leukemia: From clinical trials to real-life settings
por: Cheng, Fang, et al.
Publicado: (2023)

Perivascular cells and tissue engineering: Current applications and untapped potential
por: Avolio, Elisa, et al.
Publicado: (2017)

A Dasatinib-Induced Chylothorax Persisting After the Discontinuation of Dasatinib
por: Bradt, Nicolas, et al.
Publicado: (2022)

Transplantation of Allogeneic Pericytes Improves Myocardial Vascularization and Reduces Interstitial Fibrosis in a Swine Model of Reperfused Acute Myocardial Infarction
por: Alvino, Valeria Vincenza, et al.
Publicado: (2018)

Tyrosine kinase inhibitors: friends or foe in treatment of hepatic fibrosis?
por: Qu, Kai, et al.
Publicado: (2016)

Stem cell therapy and tissue engineering for correction of congenital heart disease
por: Avolio, Elisa, et al.
Publicado: (2015)

Treatment of COVID-19 by stage: any space left for mesenchymal stem cell therapy?
por: Spinetti, Gaia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q9hdemiv688ga8ba3vcjl8r3h5